AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Europe is putting its "ability to protect the health of its own people at risk", the CEO of FTSE 100 giant Astrazeneca has ...

The head of Britain’s largest drug company has demanded Europe ramp up spending on medicines amid fears over Donald Trump’s ...

Earnings preview of key companies reporting next week and what to look out for.

When Edward Sheldon asked the generative AI app for the best stocks to buy amid the market pullback, he was presented with ...

Platinum Asset Management’s flagship international fund initiated positions in several pharmaceutical companies in the ...

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

Drugmaker AstraZeneca has teamed up with Indian digital ... The aim of the pilot is to scan and review more than 250,000 images generated at clinics in the Greater Manchester Cancer Alliance ...

Pressurized metered-dose inhalers (pMDIs) for COPD and asthma contribute to climate change, and countries are moving away from their use.

Oncology Clinical Trial Market Roche is actively conducting pivotal trials for novel therapies targeting advanced breast cancer, aiming to ...

Naloxone Now Available Directly Through CalRx For $24: California residents can buy the overdose reversal nasal spray naloxone directly from the state through the CalRx program, Gov. Gavin Newsom ...

Biomedical Research leads at USD 1.5 billion, supporting genetic discovery and translational research.